Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Tuisku Laurinolli"'
Autor:
Satu Mustjoki, Marja Ekblom, Kimmo Porkka, Ronald Paquette, Javier Pinilla, Ingunn Dybedal, Tobias Gedde-Dahl, Marjatta Sinisalo, Bengt Simonsson, Tuisku Laurinolli, Vesa Juvonen, Martin Höglund, Juan Luis Steegmann, Sari Hernesniemi, Jane L. Liesveld, Felix T. Garzon, Pearlie K. Epling-Burnette, Panu E. Kovanen, Anna Kreutzman, Neil P. Shah, T. Petteri Arstila, Auvo Rauhala, Leif Stenke, Veli Kairisto, Henrik Hjorth-Hansen, Jukka Vakkila
Publikováno v:
Blood. 112:573-573
Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL fusion protein are an effective therapy for Philadelphia chromosome positive (Ph+) leukemia. Dasatinib, a 2nd generation pan-TKI, also inhibits wild-type kinases, which may result in unexpected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97ef1c4fe0454e0a4430a73a89acec9d
https://doi.org/10.1182/blood.v112.11.573.573
https://doi.org/10.1182/blood.v112.11.573.573
Autor:
Henrik Hjorth-Hansen, Marjatta Sinisalo, Elli Koivunen, Tuija Lundan, Juan Luis Steegmann, Marja Ekblom, Tuisku Laurinolli, Petteri Arstila, Anders Almqvist, Martin Höglund, Ronald Paquette, Satu Mustjoki, Kimmo Porkka, Neil P. Shah, Perttu Koskenvesa, Auvo Rauhala, Leif Stenke, Freja Ebeling, Bengt Simonsson
Publikováno v:
Blood. 110:2938-2938
In addition to therapeutic efficacy in imatinib-resistant BCR-ABL positive malignancies, dasatinib may have off-target immunomodulatory effects by inhibiting kinases (e.g. SRCs, c-KIT) in immune effector cells. In a proportion of patients, dasatinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::170cc9a154e2042805f5912a43c69660
https://doi.org/10.1182/blood.v110.11.2938.2938
https://doi.org/10.1182/blood.v110.11.2938.2938